HomeNewsOpinionLong COVID is real. Now the evidence is piling up

Long COVID is real. Now the evidence is piling up

A new study, led by the Icahn School of Medicine at Mount Sinai and the Yale School of Medicine and published in Nature, defines some critical differences in certain biomarkers of people with long COVID. The next step is even more critical: coming up with a way to cure them

September 28, 2023 / 11:24 IST
Story continues below Advertisement
long covid
Many people with long COVID had much lower levels of cortisol, which regulates our sense of alertness. (Source: Dan Kitwood/Getty Images/Getty Images Europe)

Finally, the hunt for answers about long COVID is yielding some clues. A new study, led by the Icahn School of Medicine at Mount Sinai and the Yale School of Medicine and published in Nature, defines some critical differences in certain biomarkers of people with long COVID. The next step is even more critical: coming up with a way to cure them.

A massive number of people in the US are dealing with lingering symptoms. Two new reports this week from the Centers for Disease Control and Prevention found that in 2022, some 18 million adults said they had ever had long COVID, with about 8.8 million currently suffering from the condition. In that time, roughly 1 million children had been affected — with about 360,000 children reporting an ongoing case.

Story continues below Advertisement

Those millions of people don’t all have the same symptoms — some experience brain fog and extreme fatigue, while others may have shortness of breath or a racing pulse — and their susceptibility to the disease is formed by a likely long list of factors. Those could include their medical histories, their previous vaccinations, prior infections, and even their genes.

Because of that, long COVID has defied simple explanations. And so far, doctors must base their diagnoses on sometimes vague symptoms, rather than on a molecule that can be measured, or a true biomarker of the disease. “Everyone wants a single biomarker, everyone wants a single treatment,” says David Putrino, director of rehabilitation innovation for the Mount Sinai Health System. “That’s not realistic for long COVID.”

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show